

AUG 21 2003

TECH CENTER 1600/2900

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/896,812
(use as many sheets as necessary)				Filing Date	June 29, 2001
				First Named Inventor	Madden, Thomas D.
				Art Unit	1615
				Examiner Name	Gollamudi S. Kishore
Page	1	of	3	Attorney Docket Number	016303-008030US

U.S. PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
TM	AA	US-5,023,087		06/11/1991	Yau-Young
TM	AB	US-5,552,156		09/03/1996	Burke
TM	AC	US-5,837,282		11/17/1998	Fenske et al.

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code	Number ⁴	Kind Code ⁵ (if known)		
TM	AD	PCT	WO 95/08986	A1	SmithKline Beecham Corporation	<input type="checkbox"/>
	AE	PCT	WO 98/17256	A1	Kirpotin, Dmitri	<input type="checkbox"/>
	AF	PCT	WO 99/51202	A2	Sequus Pharmaceuticals, Inc.	<input type="checkbox"/>
TM	AG	PCT	WO 00/23052	A1	Alza Corporation	<input type="checkbox"/>

Examiner Signature	Kishore	Date Considered	10/3/06
--------------------	---------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



TECH CENTER 1600, 2000

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/896,812
(use as many sheets as necessary)				Filing Date	June 29, 2001
Page	2	of	3	First Named Inventor	Madden, Thomas D.
				Art Unit	1615
				Examiner Name	Gollamudi S. Kishore
				Attorney Docket Number	016303-008030US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/	- AH	BURRIS III <i>et al.</i> , "Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro," <i>Journal of the National Cancer Institute</i> 84(23):1818-1820 (1992)		
	- AI	CLEMENTS <i>et al.</i> , "Antiangiogenic potential of camptothecin and topotecan," <i>Cancer Chemother. Pharmacol.</i> 44:411-416 (1999)		
	- AJ	EMERSON <i>et al.</i> , " <i>In vivo</i> antitumor activity of two new seven-substituted water-soluble camptothecin analogues," <i>Cancer Research</i> 55:603-609 (1995)		
	- AK	ERICKSON-MILLER <i>et al.</i> , "Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro," <i>Cancer Chemother. Pharmacol.</i> 39:487-472 (1997)		
	- AL	GROCHOW <i>et al.</i> , "Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer," <i>Drug Metabolism and Disposition</i> 20(5):708-713 (1992)		
	- AM	HARDMAN <i>et al.</i> , "Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: Doxorubicin, cisplatin, irinotecan or topotecan," <i>Anticancer Research</i> 19:2269-2274 (1999)		
	- AN	HSIANG <i>et al.</i> , "Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin," <i>Cancer Research</i> 48:1722-1726 (1988)		
	- AO	MADDEN <i>et al.</i> , "The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient; a survey," <i>Chemistry and Physics of Lipids</i> 53:37-46 (1990)		
	- AP	MADDEN <i>et al.</i> , "Encapsulation of topotecan in lipid-based carrier systems. Evaluation of drug stability and plasma elimination in a murine model, and comparison of antitumor efficacy against murine L1210 and B16 tumors," <i>Proc. of ASCO</i> , 17:abstract #754 (1998)		
	- AQ	MAYER <i>et al.</i> , "Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients," <i>Biochimica et Biophysica Acta</i> 1025:143-151 (1990)		
	- AR	MCCABE <i>et al.</i> , "Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan," <i>Cancer Investigation</i> 12(3):308-313 (1994)		
	- AS	O'LEARY <i>et al.</i> , "Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model," <i>Clinical Cancer Research</i> 5:181-187 (1999)		
	- AT	ORMROD and SPENCER, "Topotecan: A review of its efficacy in small cell lung cancer," <i>Drugs</i> 58(3):533-551 (1999)		
/	- AU	TARDI <i>et al.</i> , "Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models," <i>Cancer Research</i> 60:3389-3393 (2000)		


Examiner Signature	Kishore	Date Considered	10/3/06
--------------------	---------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
60015659 v1



AUG 21 2003

TECH CENTER 1600/2900

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/896,812
(use as many sheets as necessary)				Filing Date	June 29, 2001
Page	3	of	3	First Named Inventor	Madden, Thomas D.
				Art Unit	1615
				Examiner Name	Gollamudi S. Kishore
				Attorney Docket Number	016303-008030US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
<i>km</i>	AV	THOMPSON <i>et al.</i> , "Animal models for studying the action of topoisomerase I targeted drugs," <i>Biochimica et Biophysica Acta</i> 1400:301-319 (1998)		T ²
<i>km</i>	AW	WALL <i>et al.</i> , "Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from <i>Camptotheca acuminata</i> ," <i>Journal of the American Chemical Society</i> 88(16):3888-3890 (1966)		

Examiner Signature	<i>Kishore</i>	Date Considered	10/5/06
--------------------	----------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
60015659 v1